Association of selective serotonin reuptake inhibitor use with marginal bone level changes around osseointegrated dental implants: A retrospective study.

BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are used for the management of anxiety and depression. Existing evidence shows their negative impact on implant osseointegration, survival rates, and peri-implant health. Currently, there are limited data on their effect on peri-implant marginal bone levels. The primary goal of this retrospective study is to evaluate the association between SSRIs use and marginal bone level (MBL) changes around osseointegrated dental implants over time. METHODS: Records from patients who received at least one dental implant between 2010 and 2021 were reviewed. Information related to medical history, SSRI use, and the implant site was obtained from patients' electronic charts. Mesial and distal MBLs were measured relative to the implant platform on digital intraoral radiographs, taken at the time of prosthesis installation and at the most recent follow-up visit. MBL changes were calculated. RESULTS: A total of 152 dental implants from 105 patients were included. The mean follow-up period was 46.97 ± 21.87 months. The mean MBL change was significantly greater for SSRI users (0.41 ± 0.76 mm) compared to non-users (0.04 ± 0.65 mm) [MD = 0.37 mm, p = 0.00, 95% CI: (-0.61)-(-0.15 mm)]. Mesial MBL change of 0.42 ± 0.84 mm and 0.02 ± 0.71 mm was noted for SSRI users and non-users, respectively. The distal MBL change was 0.4 ± 0.93 mm and 0.07 ± 0.73 mm, respectively. Smoking, sex, and implant location did not seem to influence the MBL differences between groups. CONCLUSIONS: Use of SSRIs is associated with greater marginal bone loss around osseointegrated dental implants in function for a mean period of 3.8 years.

Association of Environmental Factors with Seasonal Intensity of Erysipelothrix rhusiopathiae Seropositivity among Arctic Caribou.

Several caribou (Rangifer tarandus) populations have been declining concurrently with increases in infectious diseases in the Arctic. Erysipelothrix rhusiopathiae, a zoonotic bacterium, was first described in 2015 as a notable cause of illness and death among several Arctic wildlife species. We investigated epidemiologic and environmental factors associated with the seroprevalence of E. rhusiopathiae in the Arctic and found that seropositivity was highest during warmer months, peaking in September, and was highest among adult males. Summer seroprevalence increases tracked with the oestrid index from the previous year, icing and snowing events, and precipitation from the same year but decreased with growing degree days in the same year. Seroprevalence of E. rhusiopathiae varied more during the later years of the study. Our findings provide key insights into the influence of environmental factors on disease prevalence that can be instrumental for anticipating and mitigating diseases associated with climate change among Arctic wildlife and human populations.

High-Voltage Lithium-Ion Battery Using Substituted LiCoPO4: Electrochemical and Safety Performance of 1.2 Ah Pouch Cell.

A LiCoPO4-based high-voltage lithium-ion battery was fabricated in the format of a 1.2 Ah pouch cell that exhibited a highly stable cycle life at a cut-off voltage of 4.9 V. The high-voltage stability was achieved using a Fe-Cr-Si multi-ion-substituted LiCoPO4 cathode and lithium bis(fluorosulfonyl)imide in 1-methyl-1-propylpyrrolidinium bis(fluorosulfony)imide as the electrolyte. Due to the improved electrochemical stability at high voltage, the cell exhibited a stable capacity retention of 91% after 290 cycles without any gas evolution related to electrolyte decomposition at high voltage. In addition to improved cycling stability, the nominal 5 V LiCoPO4 pouch cell also exhibited excellent safety performance during a nail penetration safety test compared with a state-of-the-art lithium ion battery. Meanwhile, the thermal stabilities of the 1.2 Ah pouch cell as well as the delithiated LiCoPO4 were also studied by accelerating rate calorimetry (ARC), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), and in situ X-ray diffraction (XRD) analyses and reported.

Phase Transformation of Doped LiCoPO4 during Galvanostatic Cycling.

In situ X-ray diffraction was employed to investigate the crystal structure changes in Cr/Si co-doped Li(Co,Fe)PO4 cathode material during a galvanostatic charge/discharge process at a slow rate of C/30. The evolution of the X-ray patterns revealed that the phase transformation between the Cr/Si-Li(Co,Fe)PO4 and Cr/Si-(Co,Fe)PO4 is a two-step process, which involves the formation of an intermediate compound of Cr/Si-Li0.62(Co,Fe)PO4 upon the extraction of Li ions from the pristine phase. Different from the previously reported two biphasic transition steps, the phase transformation of the Cr/Si-Li(Co,Fe)PO4 followed a solid solution and a biphasic reaction pathway at different stages of the delithiation/lithiation process, respectively.

High Capacity and High Efficiency Maple Tree-Biomass-Derived Hard Carbon as an Anode Material for Sodium-Ion Batteries.

Sodium-ion batteries (SIBs) are in the spotlight because of their potential use in large-scale energy storage devices due to the abundance and low cost of sodium-based materials. There are many SIB cathode materials under investigation but only a few candidate materials such as carbon, oxides and alloys were proposed as anodes. Among these anode materials, hard carbon shows promising performances with low operating potential and relatively high specific capacity. Unfortunately, its low initial coulombic efficiency and high cost limit its commercial applications. In this study, low-cost maple tree-biomass-derived hard carbon is tested as the anode for sodium-ion batteries. The capacity of hard carbon prepared at 1400 °C (HC-1400) reaches 337 mAh/g at 0.1 C. The initial coulombic efficiency is up to 88.03% in Sodium trifluoromethanesulfonimide (NaTFSI)/Ethylene carbonate (EC): Diethyl carbonate (DEC) electrolyte. The capacity was maintained at 92.3% after 100 cycles at 0.5 C rates. The in situ X-ray diffraction (XRD) analysis showed that no peak shift occurred during charge/discharge, supporting a finding of no sodium ion intercalates in the nano-graphite layer. Its low cost, high capacity and high coulombic efficiency indicate that hard carbon is a promising anode material for sodium-ion batteries.

Peripheral Female Genital Arousal as Assessed by Thermography Following Topical Genital Application of Alprostadil vs Placebo Arousal Gel: A Proof-of-Principle Study Without Visual Sexual Stimulation.

INTRODUCTION: Female sexual arousal disorder is a pathophysiologic state characterized clinically by persistent or recurrent inability to attain or maintain an adequate lubrication-swelling response of sexual excitement until completion of sexual activity. Prior clinical experience with alprostadil products for men with erectile dysfunction supports its use in women with female sexual arousal disorder. AIM: To compare the effect of topical alprostadil with over-the-counter (OTC) lubricant on female genital arousal in the absence of visual sexual stimuli. METHODS: Healthy premenopausal women without sexual dysfunction were recruited from the community to participate in the study. Of 17 women who consented, 10 were enrolled and completed the trial. The mean age of subjects was 32 years (range = 27-43). Study drug or placebo was applied topically to the genitals. Continuous temperature monitoring was performed. Participants completed questionnaires assessing genital sensation, effect, intensity, and duration. MAIN OUTCOME MEASURES: Change in temperature from baseline in vestibule, clitoris and vulva. RESULTS: In all 10 subjects, topical alprostadil induced a statistically significant increase in temperature of the vestibule, clitoris, and vulva compared with the OTC lubricant. The most rapid difference in genital temperature between placebo and alprostadil was seen on the vulva, which demonstrated a significant difference at approximately 9 minutes. There was a significant difference in temperature seen for the vestibule and clitoris at 11 and 19 minutes, respectively. Sixty percent of women reported being aware or conscious of genital sensations with topical alprostadil, but not with OTC lubricant. Discordance was noted in 30% of subjects who reported being aware or conscious of genital sensations with the two treatments and 10% who reported not being aware or conscious of genital sensations with either treatment. CONCLUSION: Topical alprostadil administered to healthy premenopausal women induced statistically significant, sustained increases in genital temperatures of the vestibule, clitoris, and vulva within 20 minutes compared with OTC lubricant.

Reference Values and Z Scores for Pulsed-Wave Doppler and M-Mode Measurements in Fetal Echocardiography.

BACKGROUND: Fetal echocardiography is now the standard approach for detailed investigations of fetal cardiac anatomy and function. Available studies proposing reference values for pulsed-wave Doppler (PWD) measurements are often focused on few parameters. Furthermore, the methodology used for validating these proposed reference values is sometimes insufficiently described, and parameters necessary to compute Z scores are not always available. Improved definition of reference values with adequate statistical validation is needed for proper interpretation of PWD measurements in a clinical setting. In this study, the authors propose a comprehensive set of reference values and Z score equations for fetal PWD and M-mode measurements with thorough assessment of Z score quality and validity. METHODS: Women with normal singleton pregnancies between 18 and 39 weeks of gestational age were included. A set of 57 measurements was performed, including PWD, M-mode measurements, and calculation of systolic, diastolic, and global function indices. Several parametric regressions were tested to model each measurement against gestational age. The SD was also modeled to account for heteroscedasticity. Z score equations were computed, and the proposed reference values were tested for residual association, residual heteroscedasticity, and departure from the normal distribution. RESULTS: One hundred four uncomplicated singleton pregnancies with normal fetal hearts were included. Nonlinear relationships with gestational age were found for most measurements. Parametric normalization was successful for most measurements analyzed, and it was possible to compute Z score equations with minimal residual association with gestational age, no residual heteroscedasticity, and no significant departure from the normal distribution. CONCLUSIONS: The authors propose a comprehensive set of Z score equations for 57 fetal functional measurements, some of which do not have any published reference values. These Z score equations will allow echocardiographers to more accurately identify measurements that diverge from normal and thus detect earlier potential alterations in fetal heart function.

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

CONTEXT: Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action. OBJECTIVE: The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog. DESIGN: The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d. SETTING: The study was performed at two investigational sites. PARTICIPANTS: Healthy subjects, ages 21-61 yr, were studied. INTERVENTIONS: CJC-1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study. MAIN OUTCOME MEASURES: The main outcome measures were peak concentrations and area under the curve of GH and IGF-I; standard pharmacokinetic parameters were used for CJC-1295. RESULTS: After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d. The estimated half-life of CJC-1295 was 5.8-8.1 d. After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d. No serious adverse reactions were reported. CONCLUSIONS: Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC-1295 as a therapeutic agent.